Oligonucleotide Therapeutics Society

Society News

Society News2021-08-27T10:57:04+00:00
20June, 2022

Positive Results from Tofersen VALOR Trial and OLE Integrated Data

June 20th, 2022|Categories: Perspectives on Current Science|

People diagnosed with the progressive neurodegenerative disease ALS previously had no hope of an effective treatment that could delay the onset of symptoms or extend their lifespan. However, as a result of recent advances in science and medicine, multiple oligonucleotide therapeutics are being developed to provide treatments, one of which is tofersen. Tofersen is an antisense oligonucleotide (ASO) designed ...

6June, 2022

CRISPR Babies and the Scientist Behind Their Editing

June 6th, 2022|Categories: Perspectives on Current Science|

At an international genome-editing summit in Hong Kong, MIT Technology Review reporter Antonio Regalado uncovered the existence of the CRISPR baby project. The now infamous scientist, He Jiankui, had used CRISPR-Cas9, a genetic engineering tool, to edit the CCR5 gene of three embryos with the goal of making them resistant to HIV (1). What followed the breaking story was ...

31May, 2022

CRISPR Patent Rights and Their Effect on the Industry

May 31st, 2022|Categories: Perspectives on Current Science|

A decade ago, Jennifer Doudna of the University of California, Berkley and Emmanuelle Charpentier of the Max Planck Institute for Infection Biology drafted blueprints for a groundbreaking gene editing technique. The two scientists had found a way to cut and make precise changes to DNA — a discovery that won them a Nobel Prize. This was the start of ...

9May, 2022

Could Artificial Intelligence Provide the Key to Life Saving Medicines?

May 9th, 2022|Categories: Perspectives on Current Science|

Drug discovery is time consuming and expensive, requiring trial and error screening. This means that many people have to wait decades, or a lifetime, to find a treatment for their disease. Others, especially those with rare diseases, may never have hope of a treatment. However, AI and deep learning have been used increasingly in biological research and biomedical applications ...

22April, 2022

A Novel Cocktail Drug Penetrates Heart Muscle and May Treat Nearly Half of All Patients with DMD

April 22nd, 2022|Categories: Perspectives on Current Science|

Duchenne muscular dystrophy (DMD) is a devastating disease that causes the body's muscle tissues to progressively waste away until all mobility is lost. Eventually, the heart muscle becomes fatty and fibrotic, typically leading to heart failure and death by age 30. There is no cure, and the approved drugs each help a small portion of patients and cannot target ...

Go to Top